A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Rondo Therapeutics
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
NeoImmuneTech
Tizona Therapeutics, Inc
Essen Biotech
Novartis
Sairopa B.V.
NuCana plc
Medicenna Therapeutics, Inc.
Inspirna, Inc.
GV20 Therapeutics
Carisma Therapeutics Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
Astellas Pharma Inc
Astellas Pharma Inc
Salubris Biotherapeutics Inc
ENB Therapeutics, Inc
Kineta Inc.
M.D. Anderson Cancer Center
Sheba Medical Center
Tesaro, Inc.
Vall d'Hebron Institute of Oncology
KitovPharma